Nerve stimulation plus medicine for obstructive sleep apnea in people with an implant
Tests nerve stimulation combined with atomoxetine-plus-oxybutynin in adults with obstructive sleep apnea.
Key facts
- Who runs it
- Brigham and Women's Hospital
- Where
- Boston, United StatesSee the site
- Trial code
- Registry title
- Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 24 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 1 Sept 2028
- Type of study
- Interventional, 4 groups
- Treatments tested
- Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy)
- Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition
- Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition
- Placebo; placebo comparator condition
- Record updated
- 21 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obstructive sleep apnea who have, or are scheduled to get, an implanted hypoglossal nerve stimulation device (HGNS, Inspire Medical). It tests HGNS together with the pills atomoxetine and oxybutynin (AtoOxy).
- Age
- 18 to 79 years
- Sex
- All sexes
- Disease stage
- Diagnosed obstructive sleep apnea. People must be willing to turn off HGNS for up to 6 weeks during testing.
- Earlier treatment
- Must have an HGNS device implanted, or be scheduled for implantation. The implant is needed before random assignment to treatment groups. Cannot already be taking the study medicines.
Main reasons for not taking part
- Driving for work (truck, fork-lift, taxi/uber) or a traffic accident from sleepiness in the last 2 years
- Use of SNRIs/SSRIs, anticholinergic medicines or monoamine oxidase inhibitors
- Heart failure, heart muscle disease (LVEF<50%), heart rhythm problems or stroke in the last 2 years, or high blood pressure (SBP>160 mmHg or DBP>100 mmHg)
- Low oxygen while awake (SaO2 < 92%), other sleep disorders, nerve-muscle disease, seizures, glaucoma, kidney disease (eGFR<60 ml/min/1.73m2) or liver disease
- Bladder emptying problems or enlarged prostate, certain mental health conditions, pregnancy or breast-feeding
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Ages 18 - 79 years
- Diagnosed OSA
- Implantation of a hypoglossal nerve stimulation device (HGNS, Inspire Medical) or scheduled for implantation (implantation required for randomization)
- Willingness to withhold HGNS while testing therapies (up to 6 weeks with HGNS off [with/without pharmacotherapy] to assess benefits of HGNS therapy)
Who cannot take part
- Current use of the medications under investigation
- Use of SNRIs/SSRIs or anticholinergic medications during the study
- Any uncontrolled medical condition
- Conditions likely to affect obstructive sleep apnea physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition
- Respiratory disorders other than sleep disordered breathing:; chronic hypoventilation/hypoxemia (awake SaO2 < 92% by oximetry) due to chronic obstructive pulmonary disease or other respiratory conditions
- Other sleep disorders: narcolepsy, parasomnias. Insomnia
- Contraindications for atomoxetine and oxybutynin, including:; hypersensitivity to atomoxetine or oxybutynin (angioedema or urticaria); pheochromocytoma; use of monoamine oxidase inhibitors; diagnosed benign prostatic hypertrophy, urinary retention; suspected benign prostatic hypertrophy / urinary retention based on a positive answer to either of the following questions:; "During the last month, when urinating, have you had the sensation of not emptying your bladder completely more often than 1 out of 5 times?"; "During the last month, have you had a weak urinary stream more often than 1 out of 5 times?; known untreated narrow angle glaucoma; known bipolar disorder, mania, psychosis; known history of major depressive disorder (age<24); known history of attempted suicide or suicidal ideation within one year prior to screening; known clinically significant constipation, gastric retention; known pre-existing seizure disorders; known clinically-significant kidney disorders (eGFR<60 ml/min/1.73m2); known clinically-significant liver disorders; known clinically-significant cardiovascular conditions; moderate-to-severe hypertension (SBP>160 mmHg or DBP>100 mmHg measured at baseline; average of evening and morning measures); known cardiomyopathy (LVEF<50%) or heart failure; known advanced atherosclerosis; recent cerebrovascular events (within 2 years); recent history of cardiac arrhythmias e.g., atrial fibrillation, QT prolongation (within 2 years); other serious cardiac conditions that would raise the consequences of an increase in blood pressure or heart rate; myasthenia gravis; pregnancy/breast-feeding
- Issues relating to short-term withdrawal of HGNS therapy; Excluded: Occupational driving (truck drivers, fork-lift operation, taxi/uber drivers); Excluded: History of traffic accidents attributable to sleepiness or fatigue (<2 years)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 79 years old?
Where in United States
- Brigham and Women's HospitalBoston, United StatesContact: Dillon Gilbertson, BAScTaking people
About the trial
What the trial wants to find out
Obstructive sleep apnea (OSA) is a common condition in which the airway repeatedly collapses during sleep, leading to poor sleep quality and reduced oxygen levels. Hypoglossal nerve stimulation (HGNS) is an approved treatment that uses a small implanted device to stimulate the genioglossus muscle and keep the airway open. However, some patients continue to have OSA despite using HGNS. Atomoxetine and oxybutynin, "AtoOxy", is a promising pharmacologcal therapy under investigation that has been shown to activate pharyngeal muscles-in particular non-genioglossus muscles--but appears more efficacious in some patients than others.
Read full original descriptionShow less
This study will test whether the combination of AtoOxy and HGNS can further improve breathing during sleep compared to either monotherapy alone. Participants with OSA and an HGNS device will be randomized to receive, in random order: HGNS+AtoOxy, HGNS alone (plus placebo), AtoOxy alone (HGNS device off), and placebo (HGNS device off), in a cross-over trial.
The main goal is to determine whether the combined treatment reduces the number of breathing events during sleep; the primary outcome test will compare HGNS+AtoOxy versus HGNS alone. The effect of each intervention versus placebo will also be presented.
The study will also examine how individual patient characteristics influence response to treatment.
The 4 groups in the trial
- Sequence 1Other group
HGNS+AtoOxy -\> Placebo -\> HGNS -\> AtoOxy Each participant receives all four treatment conditions ("periods") in randomized order; outcomes are analyzed as within-subject comparisons, not between sequence arms.
Treatment: Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition, and Placebo; placebo comparator condition
- Sequence 2Other group
HGNS -\> AtoOxy -\> HGNS+AtoOxy -\> Placebo Each participant receives all four treatment conditions ("periods") in randomized order; outcomes are analyzed as within-subject comparisons, not between sequence arms.
Treatment: Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition, and Placebo; placebo comparator condition
- Sequence 3Other group
AtoOxy -\> HGNS -\> Placebo -\> HGNS+AtoOxy Each participant receives all four treatment conditions ("periods") in randomized order; outcomes are analyzed as within-subject comparisons, not between sequence arms.
Treatment: Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition, and Placebo; placebo comparator condition
- Sequence 4Other group
Placebo -\> HGNS+AtoOxy -\> AtoOxy -\> HGNS Each participant receives all four treatment conditions ("periods") in randomized order; outcomes are analyzed as within-subject comparisons, not between sequence arms.
Treatment: Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition, and Placebo; placebo comparator condition
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea: A Randomized-Controlled Trial.
- Plain-language title
- Nerve stimulation plus medicine for obstructive sleep apnea in people with an implantGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07577661, who can take part
- Record updated
- 21 September 2026